This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

First Double-Blind, Placebo-Controlled Published Study Of CYPLEXINOL® Finds Significant Improvement In Pain, Stiffness And Quality Of Life In Patients With Osteoarthritis

TOMS RIVER, N.J., April 10, 2013 /PRNewswire/ --  ZyCal Bioceuticals, Inc. today announced results of the first double-blind, placebo-controlled study evaluating the benefits of Cyplexinol ® in alleviating symptoms of osteoarthritis. The results were published in the April/ May 2013 issue of Integrative Medicine: A Clinician's Journal, ( http://www.imjournal.com/open_cyp_ost) a peer-reviewed publication providing practitioners with a practical and comprehensive approach to integrating alternative therapies with conventional medicine . According to the study, participants treated with Cyplexinol ® reported a significant decrease in pain and stiffness, and a significant increase in quality of life (QOL) as compared to those treated with placebo.

Cyplexinol ® is a naturally-derived, biologically active protein complex consisting of bone morphogenetic proteins (BMPs) which stimulate bone and cartilage growth and fight inflammation. Cyplexinol ® is the active ingredient in Ostinol™ which is now available directly to consumers as an oral supplement from ZyCal Bioceuticals as well as through Chiropractors and Naturopathic physicians without a prescription.

"Using BMPs to rebuild cartilage and down-regulate inflammatory pathways is a new and exciting approach to managing the debilitating symptoms of osteoarthritis," said Richard Garian, DC, CCSP, one of the study investigators who also co-authored the paper. "For the first time, using rigorous study methods, we were able to demonstrate significant and measurable improvements in pain relief, functionality and quality of life in patients treated with an oral BMP - complex, Cyplexinol ® in as little as one week."

In this randomized, double-blind, placebo-controlled clinical trial, 87 participants diagnosed with moderate-to-severe osteoarthritis joint pain in a weight-bearing joint (the hip or knee) were randomized to receive a daily dose of either 150 mg of Cyplexinol ® or placebo for 12 weeks. Investigators measured the three primary endpoints – pain, stiffness and QOL – using the Western Ontario and McMaster University (WOMAC) Osteoarthritis Index 3.1. Change in WOMAC scores from baseline to week 1, week 6 and week 12 were calculated.   

Key findings demonstrated that participants treated with Cyplexinol ® reported:

  • Significant improvement (decrease) in pain, stiffness, and QOL was observed on the WOMAC subscales for the treatment group. The change in the group's mean scores reached significance in as early as 1 week, with a decrease in pain of 1.57 points (95% CI, 0.74-2.39; P<.0001
  • Significant improvement (decrease) in pain by 3.35 points (p<0.0001) at week 12 versus those treated with placebo who reported an increase in pain by 0.35 points (p>0.05)
  • Significant improvement (decrease) in stiffness by 2.95 points (p<0.0001) at week 12 versus those treated with placebo who reported a slight decrease in stiffness by 0.18 points (p>0.05)
  • Significant improvement (increase) in QOL by 3.12 points (p<0.0001) at week 12 versus those treated with placebo who reported a decrease in QOL by 0.40 points (p>0.05)

"The ability of bone morphogenetic proteins (BMPs) to stimulate bone and cartilage growth is well-documented in peer-reviewed literature and for decades, orthopedic surgeons have used BMPs intra-operatively to treat patients with bone-healing difficulties," said James Scaffidi, President and CEO of ZyCal Bioceuticals, Inc. "In creating Cyplexinol ®, the first oral BMP - complex, we are able to bring the benefits of BMPs to the millions of people suffering from debilitating bone and joint conditions."

About ZyCal Bioceuticals, Inc.ZyCal Bioceuticals, Inc. is an innovative nutrigenomics company focused on developing novel biologically active ingredients and products to promote bone and joint health. The company's proprietary ingredient, Cyplexinol ® is the first oral, naturally - derived BMP - complex. Cyplexinol ® works by stimulating stem cells to grow bone and cartilage tissue as well as helps in the fight against inflammation. The BMPs found in Cyplexinol ® are supported by 40 years of scientific and medical research and have been used intra-operatively by surgeons for 25 years. Cyplexinol ® is manufactured in a cGMP certified facility, available for licensing and marketed directly to consumers as Ostinol™. For more information on licensing Cyplexinol ® or to order Ostinol™ call 1-888-779-9225 ext.104 or visit www.zycalbio.com.

Contacts:Company Contact:ZyCal Bioceuticals, Inc. Marc Gawrych, (888) 779-9225 Ext. 104

Media Contact: Jennifer Ferris-Azzariti, (888) 779-9225 Ext. 110 pr@zycalbio.com

SOURCE ZyCal Bioceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs